Can a new drug help sepsis patients with weak immune systems?
NCT ID NCT07578558
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This Phase 2 trial tests whether adding the drug nogapendekin alfa inbakicept (NAI) to standard sepsis care can improve survival in critically ill adults with sepsis and persistently low lymphocyte counts (a sign of immune suppression). About 50 participants will be randomly assigned to receive either NAI injections plus standard care or standard care alone. The main goal is to see if NAI reduces deaths within 28 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nogapendekin alfa inbakicept (NAI, also known as N-803 or ANKTIVA)
What this could lead to
If successful, this could point toward a new treatment to boost the immune system in sepsis patients, potentially reducing deaths and complications.
What could go wrong
This is a small, early Phase 2 trial with only 50 participants, so results may not apply to all sepsis patients. The drug may not improve survival or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••